J&J halts COVID-19 vaccine study following unidentified participant illness

pharmafile | October 13, 2020 | News story | Manufacturing and Production, Research and Development COVID-19, J&J, JJ, Vaccine, pharma 

Johnson & Johnson has announced its decision to slam the brakes on the development programme for its COVID-19 vaccine following the illness of one of the participants

The pharma giant said that it was “committed to providing transparent updates” on the progress of the developing vaccine in line with regulatory requirements and the company’s own “high ethical and scientific principles”.

The illness has not yet been identified and J&J said it would share more info once the event had been investigated by an independent Data Safety Monitoring Board. The company aims to test the therapy in up to 60,000 patients at trial sites around the world. J&J’s shares fell 2.4% on announcement of the decision.

J&J was keen to stress that the occurrence was not out of the ordinary and is not expected to significantly impact further development, stating: “Adverse events, even those that are serious, are an expected part of any clinical study, especially large studies.”

The decision makes J&J the second company to halt a high-profile study in the COVID-19 space, after AstraZeneca chose to pause research of its candidate developed in partnership with the University of Oxford after a participant was struck with an unexplained illness.

Matt Fellows

Related Content

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

Latest content